Genomic Health Inc. (NASDAQ:GHDX)’s share price rose 1.7% during trading on Thursday . The company traded as high as $26.97 and last traded at $26.73, with a volume of 106,183 shares traded. The stock had previously closed at $26.29.

GHDX has been the topic of a number of analyst reports. Canaccord Genuity reiterated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 5th. Leerink Swann restated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 26th. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Bank of America Corp. set a $28.00 price objective on shares of Genomic Health and gave the company a “sell” rating in a research report on Wednesday, August 3rd. Finally, Jefferies Group boosted their price objective on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, August 17th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average target price of $32.44.

The firm’s 50 day moving average price is $27.97 and its 200 day moving average price is $26.57. The company’s market cap is $866.00 million.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). During the same quarter in the prior year, the company posted ($0.29) EPS. The company had revenue of $81.97 million for the quarter, compared to the consensus estimate of $81.27 million. Genomic Health’s revenue was up 16.1% compared to the same quarter last year. On average, equities research analysts forecast that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

In other Genomic Health news, insider James J. Vaughn sold 1,997 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $28.00, for a total transaction of $55,916.00. Following the completion of the transaction, the insider now owns 34,076 shares in the company, valued at $954,128. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven Shak sold 5,000 shares of the stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $25.77, for a total transaction of $128,850.00. Following the transaction, the insider now owns 332,107 shares of the company’s stock, valued at approximately $8,558,397.39. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Genomic Health stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Genomic Health Inc. (NASDAQ:GHDX) by 29.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,100 shares of the company’s stock after buying an additional 13,600 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.18% of Genomic Health worth $2,116,000 at the end of the most recent reporting period.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.